Discover
CADL
Candel Therapeutics, Inc.
9.88
2 x 7.75
2 x 12.92
bid
ask
-
0.42
4.08%
2 @ 04:00 PM
9.83 -0.05 (0.51%)
| Ytd | 74.87% | |
| 1y | 103.71% |
9.86
day range
10.87
4.35
52 week range
11.36
| Open | 10.27 | Prev Close | 10.30 | Low | 9.86 | High | 10.87 | Mkt Cap | 723.91M |
| Vol | 1.87M | Avg Vol | 2.08M | EPS | -1.01 | P/E | N/A | Forward P/E | -9.48 |
| Beta | -0.87 | Short Ratio | 7.72 | Inst. Own | 22.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 8.20 | 200-d Avg | 6.08 | 1yr Est | 19.00 |
| Income Statement | |||
| Operating Expenses | 16.28M | ||
| Research and Development Expense | 9.84M | ||
| Selling, General and Administrative Expense | 6.44M | ||
| Operating Income | -16.28M | ||
| Interest Expense | 1.56M | ||
| Net Income | -8.86M | ||
| Net Income Common Stock | -8.86M | ||
| Net Income Common Stock (USD) | -8.86M | ||
| Consolidated Income | -8.86M | ||
| Earnings per Basic Share | -0.14 | ||
| Earnings per Basic Share (USD) | -0.14 | ||
| Earnings per Diluted Share | -0.14 | ||
| Earning Before Interest & Taxes (EBIT) | -7.30M | ||
| Earning Before Interest & Taxes (USD) | -7.30M | ||
| Weighted Average Shares | 62.36M | ||
| Weighted Average Shares Diluted | 62.36M | ||
| Balance Sheet | |||
| Cash and Equivalents | 195.25M | ||
| Cash and Equivalents (USD) | 195.25M | ||
| Current Assets | 197.75M | ||
| Property, Plant & Equipment Net | 3.64M | ||
| Total Assets | 201.92M | ||
| Debt Current | 453.00K | ||
| Total Debt | 49.27M | ||
| Current Liabilities | 7.05M | ||
| Debt Non-Current | 48.82M | ||
| Total Liabilities | 63.89M | ||
| Accumulated Retained Earnings (Deficit) | -239.25M | ||
| Shareholders Equity | 138.03M | ||
| Shareholders Equity (USD) | 138.03M | ||
| Assets Non-Current | 4.17M | ||
| Total Debt (USD) | 49.27M | ||
| Deferred Revenue | 67.00K | ||
| Liabilities Non-Current | 56.84M | ||
| Trade and Non-Trade Payables | 3.04M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 241.00K | ||
| Net Cash Flow from Financing | 93.82M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 75.10M | ||
| Capital Expenditure | -675.00K | ||
| Issuance (Purchase) of Equity Shares | 93.82M | ||
| Net Cash Flow from Investing | -675.00K | ||
| Net Cash Flow from Operations | -18.04M | ||
| Share Based Compensation | 1.45M | ||